Latest news with #Vaduz
Russia Today
07-07-2025
- Business
- Russia Today
Russia sanctions trigger European trust fund crisis
Liechtenstein is scrambling to contain a crisis triggered by Western sanctions on Russia that has left hundreds of trust funds in legal limbo, the Financial Times reported on Monday. At the center of the crisis are so-called 'zombie' trusts; funds that are legally recognized but remain frozen after fiduciaries (asset managers acting on others' behalf) and board directors resigned en masse to avoid falling foul of US restrictions. 'We are talking about multibillion-dollar floating zombie trusts. And there is no solution yet. I have never seen anything like it,' said a Vaduz-based lawyer whose clients include several of the frozen entities. The Alpine microstate – a key hub for Europe's ultra-wealthy, long prized for its favorable tax and legal frameworks – adopted EU sanctions against Moscow following the escalation of the Ukraine conflict in 2022. However, US measures imposed in 2024 on Liechtenstein-based entities linked to Russian nationals have pushed the principality's vast trust industry into turmoil. Trusts hold anything from $5 million in cash to yachts, planes, family offices, and luxury real estate. According to the report, many of the affected assets belong to non-sanctioned Russians living in France, Italy, or the UAE. Last year, Washington warned Liechtenstein and other European states it could impose secondary sanctions on institutions working with certain Russian clients – even if they're not individually sanctioned. In September 2024 Liechtenstein's financial regulator advised that cutting ties with exposed clients was 'the only appropriate' way to mitigate legal and reputational risk. At least 350 entities are currently in limbo, with 85 of them orphaned. Officials and legal experts warn as many as 800 trusts could ultimately be affected. The government has launched an emergency task force to tackle the problem, the FT wrote. Justice official Martin Alge confirmed the search for new board members and liquidators is ongoing but difficult. Another concern, lawyers warn, is potential pressure from Moscow. 'There is a risk from the US but also from Russia now... an unprecedented and unparalleled risk from the other side that is equally powerful,' said Johannes Gasser, partner at Gasser Partner. Moscow has condemned the 'illegal' Western sanctions, warning of tit-for-tat measures and saying Western states are damaging their own economies. Bankers and lawyers say the crisis could spill into Liechtenstein's broader financial sector – including major banks – and threaten the country's standing as a trusted global wealth hub, known for its legal protections and insulation from geopolitical fallout. 'This is starting to be problematic for the Liechtenstein financial center,' warned MP Thomas Vogt.
Belfast Telegraph
05-07-2025
- Sport
- Belfast Telegraph
‘The Irish Cup is gone now': Rodney McAree urges Dungannon Swifts to have new focus for Euro tilt
Dungannon Swifts boss Rodney McAree has told his players in no uncertain terms that they must forget about the glory of last season's Irish Cup triumph and focus on what lies ahead, such as this month's UEFA Conference League tie against Liechtenstein outfit Vaduz. In May the Tyrone side made history by winning the Irish Cup for the first time with a dramatic penalty shoot-out success over Cliftonville, leading to great celebrations at the club and in the town which lasted for a long time.
Associated Press
04-07-2025
- Business
- Associated Press
Obyte City initial sale completes, generous referral rewards begin
Obyte City initial sale has completed. Now plots in the Obyte City are sold only for CITY, and referrers can earn 10% of what their referrals spend. VADUZ, LIECHTENSTEIN, July 4, 2025 / / -- The first chapter of Obyte City has successfully closed with more than 1,100 plots bought and over 1,300 GBYTE contributed before the June 30 deadline. The initial sale marked the debut of the CITY token and introduced users to a virtual world built on the Obyte network, where connection, collaboration, and community rewards reign supreme. Obyte City is a cypherpunk-themed digital city powered entirely by the Obyte DAG (Directed Acyclic Graph) and its decentralized Autonomous Agents. At its heart lies a simple concept: users buy plots of land on streets like Satoshi Street, Tim May avenue, etc and, when placed near other plots, both parties earn rewards like additional land and virtual houses. The platform thrives on cooperation, since neighboring users have to work together via Telegram or Discord to claim their prizes. Besides, building a house not only gives someone a permanent place in the City but also unlocks new opportunities, like assigning shortcodes (custom, human-readable, and potentially tradeable addresses) and earning from future newcomers. Behind all this is the CITY token, the currency of this community. It's minted dynamically as users interact, and burned with each fee paid, creating an economic model that balances growth with deflation. Earn by Growing the City — Referral Rewards Users aren't just buying plots: they're unlocking earning potential. Obyte City's referral system makes it easy to benefit from spreading the word. When someone purchases a plot using your personal link (which is any of your plot or house pages), you gain a referral boost: a steep increase in your chances of becoming their neighbor. In other words, you're more likely to receive the double-reward bonus —a house and two additional plots— when referrals find their place near yours. On average, referrers earn 10% of what referrals spend (excluding fees), and as more users join and buy multiple plots, this can compound significantly. It's a system designed not only to reward community-building but also to increase the likelihood of earning rewards for both parties. To start referring, users simply share a link to their plot or house through their own social media accounts, and the City page automatically makes them referrers for new users clicking the link. CITY Token Now Required for Plots With the initial GBYTE sale phase now over, users can no longer buy plots using GBYTE. All plot purchases are now paid in CITY, obtainable from other users or via decentralized exchanges and ODEX. The current price of the token is around $0.009, which would make $9.6 per plot. CITY is minted when users find neighbors and earn reward plots, and it's burned with every transaction fee, making it potentially deflationary. This built-in scarcity, combined with growing demand, opens up the possibility of long-term token appreciation. Plots can also be relinquished for a refund of their purchase price (excluding the burned fee), making the system both flexible and fair. A Living Digital Ecosystem From customizable houses and tradeable shortcodes to long-term collaboration via Telegram or Discord, Obyte City is more than a virtual map — it's a living ecosystem. Users can own multiple plots, connect with neighbors to unlock bonuses, and even participate in the City's governance. The mayor, for instance, is elected by the community and can place non-transferable 'special houses' that shape the City's layout and narrative. As the project evolves, funds raised during the token sale will go toward developing enhanced interfaces, analytics, and tools that make the City more accessible and engaging for new and current citizens alike. About Obyte Obyte is a distributed DAG-based cryptocurrency network dedicated to pioneering the next frontier of decentralization and individual autonomy. Founded in 2016, Obyte has emerged as a trailblazer in the realm of distributed ledger technologies, driven by a steadfast commitment to innovation and ideological principles that assert individual freedoms. Tony Churyumoff Obyte Foundation email us here Visit us on social media: LinkedIn Bluesky Facebook YouTube X Other Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
24-06-2025
- Business
- Yahoo
Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval
VADUZ, Liechtenstein, June 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module. Implantica submitted the last and final Module 3 of the RefluxStop® PMA application together with the response to Module 2 review findings to FDA yesterday. Module 2, the clinical module, primarily addressed what we believed were minor findings. Module 3 is focused on tests of the product such as bench testing and biocompatibility testing for the RefluxStop® device. In line with the positive feedback in the FDA PMA application process so far, the latest RefluxStop® data submitted as part of the Module 2 response, as well as in the final Module 3, is quite robust and conclusive in Implantica's opinion. We hope the newly submitted data and responses will not only continue to meet the stringent requirements for the PMA approval process but also exceed them. The continued process relies to a large extent now on FDA, which will guide Implantica in the coming steps. FDA's feedback on Module 3 is expected sometime in the autumn. Inventor of RefluxStop®, Founder and CEO of Implantica, Dr. Peter Forsell, says, "I want to extend my gratitude to U.S. FDA for this thorough evaluation process of every facet of a new technology, such as RefluxStop®. Now more than ever, I believe we are on the cusp of a new generation of much needed surgical solutions for GERD with the potential to transform the standard of care for GERD patients in the U.S.." Dr Forsell continues, "This is a significant milestone for Implantica, one we all waited for. Undoubtedly, GERD is a grave and growing issue in the U.S. today, impacting approximately 22-27% of adults in the U.S. population. With over 1300 patients treated across nearly 50 centers in Europe and excellent long-term 5-year data results from the pivotal study, I believe RefluxStop® is poised to help these hugely underserved patients in the U.S. and worldwide in the years to come!" Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):401-14. doi: 10.1016/ PMID: 23998978; PMCID: PMC3761380. Harsányi, L., Kincses, Z., Zehetner, J. et al. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc 38, 6060-6069 (2024). Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6 For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ The information was sent for publication, through the agency of the contact person set out above, on 24. June 2025, at 08:00 a.m. (CET). About Implantica Implantica is a MedTech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroomhttps:// Communityhttps:// Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 This information was brought to you by Cision The following files are available for download: Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval logo transparent 1 8 ReluxStop Product View original content: Sign in to access your portfolio
Yahoo
24-06-2025
- Business
- Yahoo
Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval
VADUZ, Liechtenstein, June 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module. Implantica submitted the last and final Module 3 of the RefluxStop® PMA application together with the response to Module 2 review findings to FDA yesterday. Module 2, the clinical module, primarily addressed what we believed were minor findings. Module 3 is focused on tests of the product such as bench testing and biocompatibility testing for the RefluxStop® device. In line with the positive feedback in the FDA PMA application process so far, the latest RefluxStop® data submitted as part of the Module 2 response, as well as in the final Module 3, is quite robust and conclusive in Implantica's opinion. We hope the newly submitted data and responses will not only continue to meet the stringent requirements for the PMA approval process but also exceed them. The continued process relies to a large extent now on FDA, which will guide Implantica in the coming steps. FDA's feedback on Module 3 is expected sometime in the autumn. Inventor of RefluxStop®, Founder and CEO of Implantica, Dr. Peter Forsell, says, "I want to extend my gratitude to U.S. FDA for this thorough evaluation process of every facet of a new technology, such as RefluxStop®. Now more than ever, I believe we are on the cusp of a new generation of much needed surgical solutions for GERD with the potential to transform the standard of care for GERD patients in the U.S.." Dr Forsell continues, "This is a significant milestone for Implantica, one we all waited for. Undoubtedly, GERD is a grave and growing issue in the U.S. today, impacting approximately 22-27% of adults in the U.S. population. With over 1300 patients treated across nearly 50 centers in Europe and excellent long-term 5-year data results from the pivotal study, I believe RefluxStop® is poised to help these hugely underserved patients in the U.S. and worldwide in the years to come!" Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):401-14. doi: 10.1016/ PMID: 23998978; PMCID: PMC3761380. Harsányi, L., Kincses, Z., Zehetner, J. et al. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc 38, 6060-6069 (2024). Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6 For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ The information was sent for publication, through the agency of the contact person set out above, on 24. June 2025, at 08:00 a.m. (CET). About Implantica Implantica is a MedTech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroomhttps:// Communityhttps:// Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 This information was brought to you by Cision The following files are available for download: Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval logo transparent 1 8 ReluxStop Product View original content:
